3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Lung Neoplasms
11
Neoplasm Metastasis
4
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome
1
Non-Small Cell Lung Cancer With EGFR Mutation
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
Inhibition, Psychological
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Erlotinib Hydrochloride
4
pembrolizumab
3
aldesleukin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
Cyclophosphamide
2
Bevacizumab
2
veliparib
1
trametinib
1
spartalizumab
1
satraplatin
1
osimertinib
1
onartuzumab
1
nintedanib
1
methyl-4-fluoro-4-deoxyglucose
1
fludarabine phosphate
1
fludarabine
1
bemarituzumab
1
anlotinib
1
aflutinib
1
Taxes
1
Sorafenib
1
Sirolimus
1
Radiotherapy, Conformal
1
Radiosurgery
1
Pentostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma of Lung
×
osimertinib
×
Clear all
NCT04770688
2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2
Completed
25 enrolled